Bioorganic and Medicinal Chemistry Letters, volume 20, issue 22, pages 6644-6648

Bromophenols as Candida albicans isocitrate lyase inhibitors

Ki-Bong Oh ¹

Heung Jeon ²

Yu Ri Han ³

Yeon Ju Lee ³

Jiyoung Park ¹

So-Hyoung Lee ¹

Dongsik Yang ²

Mihyun Kwon ²

Jongheon Shin ⁴

Hyi-Seung Lee ³

Show full list: 10 authors

Hide authors affiliations

Department of Agricultural Biotechnology, Seoul National University, Seoul 151-921, Republic of Korea. |

Department of Chemistry, Kwangwoon University, Seoul 139‐701, Republic of Korea |

Marine Natural Products Laboratory, Korea Ocean Research & Development Institute, Ansan PO Box 29, Seoul 425-600, Republic of Korea |

⁴

Natural Products Research Institute, College of Pharmacy, Seoul National University , Seoul 151-742, Republic of Korea. |

Publication type: Journal Article

Publication date: 2010-11-01

Elsevier

Journal: Bioorganic and Medicinal Chemistry Letters

scimago Q2

SJR: 0.508

CiteScore: 5.7

Impact factor: 2.5

ISSN: 0960894X, 14643405

DOI: 10.1016/j.bmcl.2010.09.015

Copy DOI

PubMed ID: 20888765

Organic Chemistry

Drug Discovery

Biochemistry

Molecular Biology

Pharmaceutical Science

Clinical Biochemistry

Molecular Medicine

Abstract

The synthesis and bioactivity of bromophenols are described. A new series of bromophenols was synthesized by reactions of corresponding phenol analogs with bromine. The synthesized compounds were tested for inhibitory activity against isocitrate lyase (ICL) of Candida albicans and antimicrobial activity against Gram-positive and, Gram-negative bacteria and fungi. Among the synthesized bromophenols, bis(3-bromo-4,5-dihydroxyphenyl)methanone ( 11 ) and (3-bromo-4,5-dihydroxyphenyl)(2,3-dibromo-4,5-dihydroxyphenyl)methanone ( 12 ) displayed potent inhibitory activities against ICL, showing a stronger inhibitory effects than were found with natural bromophenol 1 . The preliminary structure–activity relationships were investigated in order to determine the essential structural requirements for the inhibitory activities of these compounds against ICL of C. albicans .

Found

	1 2
Marine Drugs	Marine Drugs, 2, 11.11% Marine Drugs 2 publications, 11.11%
Medicinal Chemistry Research	Medicinal Chemistry Research, 2, 11.11% Medicinal Chemistry Research 2 publications, 11.11%
Journal of Natural Products	Journal of Natural Products, 2, 11.11% Journal of Natural Products 2 publications, 11.11%
Acta Pharmacologica Sinica	Acta Pharmacologica Sinica, 1, 5.56% Acta Pharmacologica Sinica 1 publication, 5.56%
Bioorganic and Medicinal Chemistry Letters	Bioorganic and Medicinal Chemistry Letters, 1, 5.56% Bioorganic and Medicinal Chemistry Letters 1 publication, 5.56%
ChemMedChem	ChemMedChem, 1, 5.56% ChemMedChem 1 publication, 5.56%
Journal of Heterocyclic Chemistry	Journal of Heterocyclic Chemistry, 1, 5.56% Journal of Heterocyclic Chemistry 1 publication, 5.56%
Organic Letters	Organic Letters, 1, 5.56% Organic Letters 1 publication, 5.56%
Journal of Enzyme Inhibition and Medicinal Chemistry	Journal of Enzyme Inhibition and Medicinal Chemistry, 1, 5.56% Journal of Enzyme Inhibition and Medicinal Chemistry 1 publication, 5.56%
Heterocycles	Heterocycles, 1, 5.56% Heterocycles 1 publication, 5.56%
BioMed Research International	BioMed Research International, 1, 5.56% BioMed Research International 1 publication, 5.56%
Progress in the chemistry of organic natural products	Progress in the chemistry of organic natural products, 1, 5.56% Progress in the chemistry of organic natural products 1 publication, 5.56%
Chemistry and Biodiversity	Chemistry and Biodiversity, 1, 5.56% Chemistry and Biodiversity 1 publication, 5.56%
Current Issues in Molecular Biology	Current Issues in Molecular Biology, 1, 5.56% Current Issues in Molecular Biology 1 publication, 5.56%
	1 2

	1 2 3 4
Springer Nature	Springer Nature, 4, 22.22% Springer Nature 4 publications, 22.22%
Wiley	Wiley, 4, 22.22% Wiley 4 publications, 22.22%
MDPI	MDPI, 3, 16.67% MDPI 3 publications, 16.67%
American Chemical Society (ACS)	American Chemical Society (ACS), 3, 16.67% American Chemical Society (ACS) 3 publications, 16.67%
Elsevier	Elsevier, 1, 5.56% Elsevier 1 publication, 5.56%
Taylor & Francis	Taylor & Francis, 1, 5.56% Taylor & Francis 1 publication, 5.56%
The Japan Institute of Heterocyclic Chemistry	The Japan Institute of Heterocyclic Chemistry, 1, 5.56% The Japan Institute of Heterocyclic Chemistry 1 publication, 5.56%
Hindawi Limited	Hindawi Limited, 1, 5.56% Hindawi Limited 1 publication, 5.56%
	1 2 3 4

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST | RIS | BibTex | MLA

Found error?

Publisher

Elsevier

Journal

Bioorganic and Medicinal Chemistry Letters

scimago Q2

SJR

0.508

CiteScore

5.7

Impact factor

2.5

ISSN

0960894X (Print)

14643405 (Electronic)

Bromophenols as Candida albicans isocitrate lyase inhibitors

Top-30

Journals

Publishers

Are you a researcher?